Lactation is associated with significant alterations in both body composition and bone mass. Systemic and local skeletal factors such as RANKL, PTHrP, calcitonin, and estrogen are known to regulate bone remodeling during and after lactation. FGF21 may function as an endocrine factor to regulate body composition changes during lactation by inducing gluconeogenesis and fatty acid oxidation. In this study, we hypothesized that the metabolic changes during lactation were due in part to increased circulating FGF-21, which in turn could accentuate bone loss. We longitudinally characterized body composition in C57BL/6J (B6) mice during (d7Lac and d21Lac) and after normal lactation (d21Post). At day 7(d7Lac) of lactation, areal bone density declined by 10% (aBMD: pϽ0.001) bone resorption increased (pϽ0.0001), percent fat decreased by 20%, energy expenditure increased (pϽ0.01), and markers of brown-like adipogenesis were suppressed in the inguinal depot and in pre-formed brown adipose tissue. At d7Lac there was a 2.4 fold increase in serum FGF-21 vs. baseline (pϽ0.0001), a 8-fold increase in hepatic FGF-21 mRNA (pϽ0.03), a 2-fold increase in undercarboxylated osteocalcin (pϽ0.01) and enhanced insulin sensitivity. Recovery of total aBMD was noted at d21Lac, while femoral trabecular bone volume fraction (BV/TV) was still reduced (pϽ0.01). Since FGF-21 levels rose rapidly at d7Lac in B6 lactating mice, we next examined lactating mice with a deletion in the Fgf21 gene. Trabecular as well as cortical bone mass were maintained throughout lactation in FGF-21-/-mice, while pup growth was normal. Compared to lactating control mice, lactating FGF-21-/-mice exhibited an increase in bone formation, but no change in bone resorption. In conclusion, in addition to changes in calcitropic hormones, systemic FGF-21 plays a role in skeletal remodeling and changes in body composition during lactation in B6 mice.
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L
actation is essential for mammalian survival (1, 2) . Previous work established there was uncoupling of bone remodeling during the early phases of lactation in mice, rats and humans, with high rates of bone resorption and decreased bone formation (3) (4) (5) (6) (7) . Uncoupling in skeletal remodeling has been variously ascribed to high circulating RANKL concentrations, low estrogen levels, and increased PTHrP, although other factors are likely to be operative (8 -10) . The postlactation period is characterized by skeletal recovery through poorly understood mechanisms although it has been related to osteoclast apoptosis, refilling of lacunae by osteocytes, and an independent anabolic-rebuilding period (4, (11) (12) . Several candidates have been suggested as mediators of the latter state including estrogen, oxytocin, PTHrP, IGF-I, and others (11, 13, 14) . Conditional deletion of PTHrP in mammary tissue reduced the magnitude of bone loss between days 4 -12 of lactation but the extent of skeletal recovery was not examined (8, 15) . It is also unclear what factors regulate the body composition changes that accompany lactation. FGF21 is a member of a subfamily of FGFs (which include FGF15/19 and FGF23), which lack the FGF heparin-binding domain. FGF21 functions as an endocrine factor by inducing gluconeogenesis and fatty acid oxidation during stressful conditions such as fasting, when increased substrate utilization is required to maintain homeostasis (16) . In this study, we hypothesized that the metabolic changes during lactation were due in part to increased circulating FGF-21, which in turn could accentuate bone loss.
Immediately after lactation there are also dramatic changes in body composition and a shift in energy utilization from mammary tissue towards bone to ensure skeletal restoration. In this study we systematically examined whether the skeletal changes during lactation could be related to metabolic determinants as well as calciotropic factors. Our results confirm there are profound, but reversible changes in whole body and skeletal metabolism during and after lactation. We also found that FGF-21 is one of several factors modulating substrate utilization and bone turnover during lactation.
Materials and Methods

Animals
C57BL/6J (B6) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Eight-week-old C57BL/6J female mice were mated and after the mice became pregnant, males were removed. After birth lactating females were studied at day 7 (d7Lac), day 21 (d21Lac) and day 21-post lactation (d21Post). Mice were weaned at 21 days after birth, therefore the d7Lac time point examines early lactation and the d21Lac time point examines late lactation, assuming lactation ends shortly after weaning at 21 days after birth. The d21Post time point examines the effect of lactation 21 days post wean. Age-matched nonlactating C57BL/6J control mice were also maintained for each time point (d7Lac vs. 12wk nonlactating control; d21Lac vs. 15wk nonlactating control and d21Post vs. 20wk nonlactating control). All age matched animals were Ϯ 5 days of lactating animals, this allows us to take into consideration variation of the time of conception. FGF-21 null mice have been described (16) . The FGF-21 null mice were kept on a B6 background (backcrossed for at least 6 generations). FGF-21 KO and WT littermates from the last backcross were then bred as WTxWT and KOxKO, which provided the mice for all the FGF-21 studies. FGF-21 KO and WT mice were set up for mating at 10 weeks of age and samples were harvested at day 14 of lactation (d14Lac) with age-matched nonlactating virgin controls (Ctrl; 16wks old). Mice were maintained at 25°C on a 14-hour dark, 10-hour light cycle on standard regular chow (Harlan Tekland, Indianapolis, IN, USA). All the mice were fed standard chow containing 4% fat ad libitum. All experimental studies and procedures involving mice were reviewed and approved by the Institutional Animal Care and Use Committee of MMCRI (Scarborough, ME, USA) and The University of Texas Southwestern Medical Center (Dallas, TX, USA).
Dual-energy X-ray absorptiometry
Dual-energy X-ray absorptiometry (DXA) for whole-body and femoral areal bone mineral density (BMD) (aBMD, mg/cm 2 ) and body composition exclusive of the head were performed using the PIXImus (GE Lunar, Fairfield, CT, USA) as described previously (10) . The PIXImus was calibrated daily with a phantom provided by the manufacturer.
Microcomputed tomography (CT)
Microarchitecture of the distal trabecular bone and midshaft cortical bone of the femur was analyzed by CT (resolution 10 m, VivaCT-40; Scanco Medical AG, Bassersdorf, Switzerland) as published previously (17) . The VivaCT-40 is calibrated weekly using a phantom provided by Scanco Medical AG. Trabecular BV/TV and microarchitecture were evaluated in the secondary spongiosa, starting proximately at 0.6 mm proximal to the distal femoral growth plate, and extending proximally 1.5 mm. Measurements included bone volume/total volume (BV/ TV), trabecular number (Tb.N.), trabecular thickness (Tb.Th.) and trabecular separation (Tb.Sp.). Scans for the cortical region were measured at the midpoint of each femur measuring the average bone area (BA), total cross-sectional area (TA), bone area/total area (BA/TA), cortical thickness (Ct.Th.) and cortical porosity (Ct.Po.).
Osmium CT analysis for marrow adipose tissue
Staining for marrow fat requires the use of osmium tetraoxide (OsO 4 ) in a four-step procedure as reported previously as a modification of the CT protocol (17, 18) . Mouse tibia were isolated and then fixed in 10% neutral buffered formalin. Tibias were then decalcified with EDTA at 4°C for 14 days. The decalcified bones were immersed in OsO 4 for 48 hours at room temperature prior to imaging with a VivaCT-40 (Scanco Medical AG, Bassersdorf, Switzerland) using a voxel size of 10 m. Briefly, four volumes of interest (VOI) within the marrow space, extending 230 mm, were defined by their position along the z-axis. The first VOI began 230 mm from the proximal end of the tibia, and each subsequent VOI began 1.2 mm distal to the previous VOI. The fractional volume of osmium-stained fat within the VOI's was determined using the Scanco 3D bone morphometry evaluation program with a threshold of 420 and Gaussian filtering (s ϭ 0.8, support ϭ 1).
Bone histomorphometry
Static and dynamic histomorphometry measures were analyzed between lactating and age-matched nonlactating control C57BL/6J mice at 12wk vs. d7Lac, 15wk vs. d21Lac and 20wk vs. d21Post lactation. FGF-21 KO and WT mice were analyzed at d14Lac vs. 13wk nonlactating controls. Mice were injected with 20 mg/kg calcein and demeclocycline IP 9 days and 2 days, respectively, before sample collection. Femurs were analyzed as described and standard nomenclature was used (17, 19) .
RNA isolation and quantitative real-time PCR
Total RNA was prepared using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) for liver and mammary tissue or using a standard TRIzol (Sigma, St. Louis, MO, USA) method for tibias. Total RNA was extracted from lipid depots using an RNeasy Lipid Tissue Mini Kit (Qiagen, Valencia, CA, USA). cDNA was generated using a random hexamer and reverse transcriptase (SuperscriptIII; Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. mRNA expression analysis was carried out using an iQ SYBR Green Supermix with an iQ5 thermal cycler and detection system (Bio-Rad, Hercules, CA, USA). Relative expression of mRNA was determined after normalization to hypoxanthine guanine phosphoribosyl transferase (Hprt) levels in addition to ␤-2 microglobulin (B2M) (inguinial fat, liver), 18s (interscapular fat) or ribosomal protein L13A (Rpl13a) (mammary, tibia). Primers were designed and tested to be 95% to 100% efficient by PrimerDesign (Southampton, UK) unless otherwise noted. All primer sequences are listed (Table SI) .
Serum biochemical parameters
Serum concentrations of amino-terminal propeptide of type 1 procollagen (P1NP), cross-linked C-telopeptide (CTX) and insulin growth factor 1 (IGF1) were measured with the Rat/Mouse P1NP enzyme immunoassay (EIA), the RatLaps EIA and the Mouse IGF1 High Sensitivity immunoassay (EIA), respectively (Immunodiagnostic Systems, Scottsdale, AZ, USA). The assay sensitivities were 0.7, 2 and 63 ng/ml for P1NP, CTX and IGF1 respectively. The intraassay variations were 6.3%, 6.9% and 6.8% and the interassay variations were 8.5%, 12% and 7.3%, respectively. Serum concentrations of insulin and sclerostin were measured with the Mouse Insulin immunoassay (EIA), and Mouse Sclerostin immunoassay (EIA), respectively (ALPCO, Salem, NH, USA). The assay sensitivities were 0.12 ng/mL and 17.4 pg/mL for insulin and sclersotin, respectively. The intraassay variations were 3.7% and 6.4% and the interassay variations were 3.2% and 10.3% respectively. Serum concentration of fibroblast growth factor 21 (FGF-21) was measured with the Mouse/Rat FGF-21 immunoassay (EIA) (BioVendor, Candler, NC, USA). The assay sensitivity was 18.4 pg/mL, the intraassay variation was 8.4% and interassay variation was 8.7%. Serum concentration of osteocalcin (OCN) was measured with Mouse Osteocalcin immunoassay (EIA) (Biomedical Technologies, Stoughton, MA, USA). The assay sensitivity was 1 ng/mL, the intraassay variation was 6% and the interassay variation was 8%. Undercarboxylated osteocalcin (Glu13 OCn) was performed as previously described (20) . All measurements were performed in duplicate.
Indirect calorimetry
Indirect calorimetry measurements were performed using the Promethion Metabolic Cage System (Sable Systems, Las Vegas, NV, USA) located in the Physiology Core Department of Maine Medical Research Institute as previously described (21) . Mice were subjected to a standard 14h-light/10h-dark cycle during the study, which consisted of a 12-hour acclimation period followed by a 72-hour sampling duration. Data shown are representative of the 24-hour average of this period. Correlations were performed between energy expenditure (EE) and lean, fat and total body mass to determine if these variables could explain changes in energy expenditure (22) (23) 
Insulin tolerance tests
C57BL/6J mice were tested for insulin tolerance at d7Lac and compared to age-matched 12wk old nonlactating controls. Mice were fed ad libitum and injected I.P. with insulin at a dose of 1U/Kg. Glucose was measured at 0, 15, 30, 45, 60, and 120 minutes post injection using an OneTouch Ultra Glucometer (LifeScan, Inc., Milpitas, California) (24) .
Statistical Analysis
Data are expressed as mean Ϯ S.E.M. Results were analyzed for statistically significant differences using Student's t test or ANOVA followed by Tukey's multiple comparison test or Kruskal-Wallis test with Dunn's multiple comparison test where appropriate. Multiple regression analysis was used to adjust for group and lean mass for energy expenditure studies. All statistics, including regression analysis, were performed with Prism 6 statistical software (Graph Pad Software, Inc., La Jolla, CA, USA). Statistical significance was set at P Ͻ .05.
Results
Areal BMD was lost and then regained in lactating mice
For areal bone density measurements by DXA, B6 mice (n ϭ 9 -11/group) were measured longitudinally at biweekly intervals during lactation and post lactation. The controls were nonlactating B6 mice of the same age and gender measured longitudinally. Total areal BMD were significantly reduced at d7Lac (P Ͻ .001) compared to nonlactating controls at 12 weeks of age and by d21Lac had returned to d7Lac levels ( Table 1) . At d21Lac, the difference in aBMD (femoral and total) compared to nonlactating controls at 15 weeks persisted (Table 1 ; P Ͻ .001). During the weaning period at d21Post, total and femoral aBMD increased significantly compared to either d7Lac or d21Lac measurements, but femoral aBMD did not reach levels in the 20wk nonlactating controls (Table  1) .
Lactation alters microarchitecture through trabecular and cortical bone loss
B6 mice were sacrificed at specific time intervals during and post lactation that were identical to the longitudinal studies by DXA. Hence the CT and histomorphometry were cross-sectional studies of cohorts at distinct ages. Femoral BV/TV was lower in the lactating mice vs. controls at all time points (Table 2, Figure 1A ; P Ͻ .05). Consistent with the changes in trabecular bone volume fraction, lactating mice had lower connectivity density and lower trabecular number, at d7Lac compared to controls ( Table 2 , P Ͻ .05). At d7Lac mice also displayed a nonsignificant trend for higher trabecular spacing and thinner trabeculae compared to controls (Table 2) . Trabecular BV/TV and trabecular number continued to decrease, and trabecular spacing continued to increase, at both d21Lac and d21Post (compared to d7Lac and age-matched controls). In the femoral midshaft, lactating mice had a nonsignificant increase in total cross sectional area (Tt.Ar, Table 2 ) but reduced cortical thickness and cortical area fraction at d7Lac (Table 2) . At d21Lac, cortical thickness was reduced further (P Ͻ .005 compared to d7Lac) and remained significantly lower than controls. However, at d21Post, cortical thickness was significantly improved compared to d21Lac (Table 2) . Cortical porosity was significantly higher in lactating animals compared to controls, however by d21Post lactation porosity was reduced compared to d21Lac, (Ct.Po, Table 2 ). At d21Post, trabecular bone mass and microarchitecture did not fully recover and remained lower than age-matched nonlactating controls, unlike areal BMD which was restored but remained slightly but not significantly lower than age matched controls (Tables 1 & 2) .
Lactation is associated with uncoupled bone remodeling
Histomorphometry of the proximal tibia was done at d7Lac, d21Lac, and d21Post using calcein and demeclocycline labeling for trabecular bone surface. Bone formation rate (BFR/BS) was increased by 33% between d7Lac and d21Post (P Ͻ .05) whereas eroded surfaces/bone surfaces dropped dramatically from 2% at d7Lac to 0.37% at d21Post (P Ͻ .05) consistent with trends toward reduced osteoclast number per bone perimeter (2.27 to 0.47; P ϭ .069) and reduced percent osteoclast surface (5.85 to 1.36; P ϭ .09) (Figure 1B-C, Table SII) .
Bone turnover markers generally confirmed the changes seen by histomorphometry. Notably, serum Ctelopeptide (Rat Laps) showed a marked increase at d7Lac (peak resorption) vs. 12 weeks old nonlactating controls ( Figure 1D ; P Ͻ .001) then returned to prelactation levels at d21Lac and d21Post lactation. On the other hand, RANKL concentrations were unchanged between baseline and d7Lac of lactation (data not shown). Total serum osteocalcin showed a marked increase at d7Lac and d21Lac compared to 12wk old nonlactating controls (Figure 1E ; P Ͻ .001). For P1NP, another marker of bone formation, there was a statistically significant doubling at d7Lac (P Ͻ .001) compared to age-matched nonlactating control similar to the increase in C-telopeptide at d7Lac ( Figure 1F ). Serotonin, a hormone that regulates PTHrp in mammary tissue (9, 10) , increased at d7Lac compared to age-matched controls (Table 3 ; P Ͻ .001). Serum sclerostin at d21Lac was 50% lower in the lactating animals compared to controls ( Figure 1G ; P Ͻ .001).
Gene expression was performed by whole bone plus marrow analysis using qRT-PCR at, d7Lac and d21Lac as well as d21Post compared to 12wk old nonlactating control. Osterix and Atf4, markers of osteoblast differentiation, were markedly suppressed at d7Lac compared to baseline ( Figure 1I ; P Ͻ .008, and P Ͻ .04). The osteoclastogenesis inhibitory factor Opg was also down regulated by 45% at d7Lac vs. baseline ( Figure 1H ; P Ͻ .002). Osterix and Atf4 expression levels returned to normal by d21Lac (Table SIII) . The expression of osteoclast recruitment factor Rankl was unchanged for all time points (Table SIII). In respect to markers of fat metabolism in the bone marrow, Ppar␣, a mediator of fatty acid oxidation and a regulator of FGF-21, and PDK4, a marker of marker of fatty acid metabolism were both slightly but not significantly increased at d7Lac (Table SIII) . Despite the marked decrement in trabecular bone volume fraction, the absolute volume of marrow adipose tissue using osmium staining with CT of the tibia at four distinct sites dem- Body composition and metabolic changes were present during and after lactation Total body weight in grams was higher in the lactating dams vs. agematched controls at d7Lac and d21Lac (Table 1 ). There was a 21% reduction in percent body fat at d7Lac in lactating mice vs. 12-week nonlactating controls, however, percent body fat was not different at d21Lac. By d21Post lactation, percent body fat was 30% lower in the dams that had lactated vs. controls (Table 1 ; P Ͻ .05). Changes in percent fat were not due to changes in absolute fat mass, which was not different at d7Lac and d21Lac (Table  1) . Lean mass was similar from d7Lac to d21Lac but higher than controls at all time points and this was associated with a marked increase in energy expenditure (EE; P Ͻ .005) in the lactating mice vs. controls ( Figure S1A ). At d21Post lactation, lean mass decreased significantly compared to d7Lac and d21Lac mice, yet was still higher than age-matched nonlactating controls. Adjusting EE for group and lean mass revealed no difference between lactating and control mice when a multiple regression model was used (r 2 for lean ϭ 0.65; P ϭ .03; f value of model ϭ 0.0018, Figure  S1B ). However, food consumption of the lactating mice was markedly increased and total activity was slightly reduced without a longitudinal change in total body weight, consistent with a shunting of nutrients towards mammary tissue ( Figure  S1C-D) .
To determine the mechanism for lactation-induced changes in body composition we next investigated the effects of lactation on gene expression in inguinal white adipose tissue (WAT), interscapular brown adipose tissue (BAT), and the mammary gland. In inguinal fat there was global suppression of Pgc1␣ and Ucp1, markers of brown-like adipogenesis, at d7Lac vs. 12-week nonlactating control mice (Figure 3A -B; P Ͻ .002). This reduction persisted for Pgc1␣ at d21Lac but returned to comparable expression levels relative to control by d21Post lactation. Ucp1 mRNA expression levels increased 2 fold by d21Post lactation ( Figure 3B ). Pdk4, an enzyme that can promote fatty acid generation was more than 2 fold increased in inguinal fat relative to control at d7Lac (P Ͻ .0001). In BAT, a similar pattern was noted; there was global suppression of Ucp1 mRNA (85% reduction, P Ͻ .0001) and Pgc1␤, a transcriptional coactivator that modulates mitochondrial biogenesis and energy homeostasis, was suppressed by 40% (P Ͻ .0002) at d7Lac vs. 12-week nonlactating control mice ( Figure  D-E) . In mammary tissue, Ucp1 and Pgc1␤ mRNA were up regulated significantly (P Ͻ .0001) at d7Lac whereas Pgc1␣ transcripts were suppressed (Figure 3F-I; P Ͻ .002). Due to the magnitude and acceleration of changes in body composition associated with the high rates of bone resorption during lactation, we next investigated factors that might contribute to those effects. Undercarboxylated osteocalcin, (Glu13 OCn), a peptide fragment that enhances insulin sensitivity and secretion, was 25.1 Ϯ 1.2 ng/ml at d7Lac, the peak of bone resorption. However, at d21Lac and then d21Post, Glu13 Ocn levels declined to levels of 12.1 Ϯ 3.3 ng/ml (P Ͻ .01, d21Lac vs. d7Lac) and 12.0 Ϯ 2.5 ng/ml respectively (P Ͻ .01, d21Post vs. d7Lac). Serum leptin was not different at d7Lac, a time when fat mass was lost (Table 3) . Adiponectin levels at d7Lac were nearly 50% lower than baseline levels (P Ͻ .001) reflecting the acute changes in adipose tissue; in contrast serotonin concentrations increased significantly at d7Lac vs. controls (Table 3 ; P Ͻ .001).
Insulin concentrations were lowest at baseline and d7Lac but by d21Lac were increased significantly from baseline: 0.445 Ϯ 0.066 vs. 0.729 Ϯ 0.119 (Table 3 ; P Ͻ .05). In the post lactation phase, serum insulin levels returned to baseline values. Insulin-like growth factor-I (IGF-I) serum levels increased nearly 50% from d7Lac to d21Post (P Ͻ .0002) and were greater than control at d21Post (Table 3 ; P ϭ .01). Fibroblast growth factor-21 (FGF-21), a counter-regulatory factor secreted by the liver during states of substrate insufficiency, revealed a different pattern: serum levels of FGF-21 rose more than 2.4 fold from baseline to d7Lac (P Ͻ .0001) and then remained elevated at d21Lac (P ϭ .005) and d21Post (P ϭ .0001), although less than d7Lac (Table 3) . Consistent with circulating changes, hepatic Fgf21 mRNA was increased 8 fold in the liver at d7Lac over baseline (P Ͻ .03, data not shown).
Due to changes in serum insulin during lactation and the rise in endogenous insulin sensitizing peptides such as undercarboxylated osteocalcin and FGF-21, we performed an insulin tolerance test (ITT) at d7Lac in nonlactating age-matched B6 controls (n ϭ 8) and lactating B6 mice (n ϭ 6).
Random fed glucose at d7Lac was significantly lower than control serum from age matched mice ( Figure  4A ; P Ͻ .05). During ITT, blood glucose of lactating mice reached the nadir sooner and the nadir was lower compared to nonlactating B6 mice ( Figure 4B ; P Ͻ .001). After day 14 of lactation, the increase in insulin sensitivity was no longer present with a glucose pattern nearly identical to age-matched controls (data not shown).
FGF-21 null mice (F21-KO) do not lose bone with lactation
To determine whether FGF-21 was a major mediator of lactation-induced changes in bone remodeling and energy metabolism, we next compared FGF-21 null (F21-KO) lactating dams at day 14 (d14Lac) to age-matched nonlactating virgin controls (Ctrl; 16wks old). Day 14 of lactation was chosen as a time point because a priori we expected to see peak lactation-induced bone loss. Pup size and growth were similar between the two genotypes across lactation and post weaning. CT analyses revealed that significant lactation-induced trabecular and cortical bone loss occurred in WT mice, but was not present in F21-KO mice ( Figure 5A-D) . Histomorphometry showed Representative images of osmium staining for marrow adiposity. C57BL/6J females at d21Lac were compared to 15wk old nonlactating age-matched controls. Tibias were stained for marrow fat using osmium tetraoxide (OsO 4 ) and then imaged using uCT using a voxel size of 10 m. that osteoclast number and surface were significantly increased in d14Lac WT mice compared to age matched controls, but not in F21-KO mice ( Figure 5E ; P Ͻ .005); similarly, osteoblast number and surface were decreased on d14Lac compared to age-matched controls in WT mice, but not in F21-KO mice ( Figure 5F ; P Ͻ .001). Serum CTX-1 (RatLaps) was increased on d14Lac in WT mice compared to age matched controls (P Ͻ .05), but this response was largely absent in F21-KO mice ( Figure 5G ). Serum P1NP on d14Lac was comparable to age matched controls in WT mice despite the increased bone resorption; in contrast, P1NP was increased on d14Lac compared to age matched controls in F21-KO mice ( Figure 5H ; P Ͻ .001).
Discussion
In the current study we demonstrated that lactation affects not only skeletal remodeling but also whole body metabolism in mice. In addition we noted several features of lactation in B6 mice that are potentially relevant and translatable. First, bone loss in lactating mice is significant and involves both cortical and trabecular elements, although each compartment responds distinctly. Remarkably, the global loss of bone mass is associated with a compensatory increase in femoral cross sectional area, a mechanism that likely maintains bone strength during lactation and recovery (11) (12) (25) (26) (27) . A recent longitudinal study in humans confirmed that repetitive and prolonged lactation protects against hip fractures late in life, possibly due to this compensation in the cortical compartment (28) . In contrast to the cortex where bone mass recovered completely, trabecular bone was lost and never fully restored in the B6 mice, possibly because there is normally some concomitant agerelated bone loss in B6 females during the observation period (29) . It would be important to know, through the use of high-resolution uCT imaging whether lactating mothers have full trabecular bone recovery following lactation and whether the compensatory increase in femoral cross sectional area is responsible for the reduction in hip fractures late in life among women with repeated and prolonged lactation periods. The bone loss of lactation is due to both accelerated bone resorption and suppressed bone formation. The mechanisms that lead to a reduction in bone formation during the early phases of lactation are multifactorial. However, high levels of FGF-21, suppressed IGF-I, increased circulating serotonin or changes in local or circulating sclerostin might all contribute to a down regulation in bone formation. For example, serotonin regulates local PTHrP production in mammary tissue in response to elevated prolactin levels (9, 10). Increased circulating serotonin from mammary tissue rather than from the gut could lead to lower bone formation via inhibition of the Wnt signaling pathway. Sclerostin is released from osteocytes within the remodeling unit and could suppress bone formation at a time when calcium requirements in other tissues are very high (30) . Increased circulating FGF-21 is another possible cause of reduced bone formation since transgenic FGF-21 mice have markedly suppressed rates of bone formation primarily due to the increased activity of PPAR␥ as well as suppression of Wnt signaling (31) .
A second notable finding in our study was the skeletal recovery of B6 mice post weaning and the relationship to changes in metabolic factors. Interestingly, the restoration of bone mass is time and site specific such that total aBMD is recovered more rapidly than femoral aBMD, which may be due to the contribution from trabecular elements in the proximal and distal femur to femoral aBMD measurements. Although skeletal recovery has been reported previously after lactation, the association with systemic and local metabolic factors has not been described (32, 33) . There were only modest changes in gene expression within the bone marrow for genes related to adiposity, but these were consistent with the decline in bone marrow adiposity quantitated by osmium CT in the lactating dams. Importantly, serum sclerostin levels declined at d21Lac, and these changes were reflected in the histomorphometry at d21Lac and changes in biochemical markers of bone turnover. In contrast to these data, another recent examination of lactation found that sclerostin gene expression was reduced somewhat later in the process of lactation, at d7 post weaning (27) .
Third, in this study we found that high levels of FGF-21 are related to changes in body composition and skeletal remodeling. The high metabolic demand during lactation is also reflected by the reduction in marrow adipose tissue at d21Lac. At the same time there was a marked increase in circulating FGF-21 and an increase in insulin sensitivity at d7Lac. The timing of this sensitivity is remarkable in that it also coincided with the greatest bone resorption (ie, d7Lac) during lactation. Both the Karsenty and Clemens groups have shown that insulin secretion and sensitivity are increased during states of accelerated bone turnover in mice through release of undercarboxylated osteocalcin from the bone matrix (35) (36) (37) . Undercarboxylated osteocalcin (Glu13 Ocn) peaked at d7Lac vs. baseline and returned to control values at d21Lac and d21Post. Thus, insulin sensitivity during lactation could be related to high concentrations of circulating FGF-21 and the release of matrix peptides such as undercarboxylated osteocalcin as well as other hormonal factors.
In the FGF-21 null mice the cellular mechanism for skeletal resistance during the high calcium demand of lactation is likely related to a relative reduction in bone resorption compared to wild-type lactating mice. This was confirmed by the near absence of change in CTx levels during lactation in the FGF-21 null mice. Similarly it was reported that in both male and female FGF-21 null mice, bone resorption was consistently reduced, and the RANKL/OPG ratio low, although the mechanism for these changes was not well delineated (31) . Moreover, it is uncertain why FGF-21 null osteoclasts do not respond to changes in calciotropic hormones and the absence of estrogen during the high calcium demands of lactation. Interestingly, despite the absence of significant bone resorption in the FGF-21 nulls, bone formation was not suppressed ( Figure 5F ) suggesting an uncoupling in the remodeling unit favoring skeletal protection rather than loss. It is conceivable that the FGF-21 null mice have a different pattern of sclerostin expression compared to lactating B6 mice, which have high levels during early lactation but decrease by d21Lac. Alternatively, osteoclast number is not altered in FGF-21 null mice. Hence these cells may continue to release coupling factors that enhance bone formation even though the osteoclasts are not actively resorbing bone. Furthermore, we could not deter-mine from our studies whether osteocytic osteolysis during lactation was the chief mechanism for calcium release from the skeleton in these mice, although this is a strong possibility (26) . Finally, changes in FGF-21 could also be important in the recovery phase post lactation. It is conceivable that a drop in FGF-21 could lead to a rebound enhancement in bone formation and subsequent decline in bone resorption, although several factors are likely involved. For example, circulating IGF-I was increased post lactation in C57BL/6J mice (33) . Since FGF-21 can regulate hepatic IGF-I through suppression of growth hormone (GH) mediated STAT 5 signaling, a decline in FGF-21 and an increase in IGF-I may combine to allow recovery of BMD post lactation.
In conclusion, we established that whole body metabolic changes accompany uncoupling in bone remodeling during lactation. Increased circulating FGF-21 affects whole body metabolism, insulin sensitivity and skeletal remodeling during this period. Further studies are needed to define the mechanisms implicit in the FGF-21 skeletal response and to determine other skeletal factors that may regulate whole body metabolism.
